[SKYSTAR BIO-PHARMACEUTICAL COMPANY ANNOUNCES RECEIPT OF NASDAQ NOTIFICATION LETTER Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI), a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, announced that on November 17, 2015, it received a letter from NASDAQ Stock Market indicating that that Skystar failed to comply with Nasdaq’s filing requirement set forth in Listing Rule 5250(c)(1) (the “Rule”)] []

[SKYSTAR BIO-PHARMACEUTICAL COMPANY ANNOUNCES RECEIPT OF NASDAQ NON-COMPLIANCE LETTER DUE TO DELAY IN FILING FORM 10-Q Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI) (the “Company”), a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, announced today that on August 19, 2015, the Company received a notification from the Nasdaq Stock Market (“Nasdaq”) informing the Company that because it] []

[SKYSTAR BIO-PHARMACEUTICAL COMPANY ANNOUNCES RECEIPT OF Xi’an, China, May 22, 2015 – Skystar Bio-Pharmaceutical Company (Nasdaq: SKBI), a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, announced today that the Company received a notification from the Nasdaq Stock Market (“Nasdaq”) informing the Company that since it had not filed its Quarterly Report on Form 10-Q for] [By Electronic Delivery to: bing@skystarbio-pharmaceutical.com; aorudjev@schiffhardin.com; scramer@skystarbio-pharmaceutical.com May 21, 2015 Mr. Bing Mei Chief Financial Officer Skystar Bio-Pharmaceutical Company 4/F Building B, Chuangye Square, No. 48 Keji Road Gaoxin District, Xi’an Shaanxi Province, P.R. China Re: Skystar Bio-Pharmaceutical Company (the “Company”) Nasdaq Symbol: SKBI Dear Mr. Mei: As you know, since we have not received the Company’s Form 10-Q for] []